Newsroom

DENVER--(BUSINESS WIRE)--Rivalry Capital Launches as Next-Generation Private Equity Firm Focusing on Healthcare Transformation...

SOUTHLAKE, Texas e YOKNEAM, Israele--(BUSINESS WIRE)--Rapid Medical™, un importante sviluppatore di dispositivi endovascolari attivi, annuncia la conclusione dell'arruolamento di pazienti nello studio clinico multicentrico, randomizzato DISTALS, volto a valutare il dispositivo TIGERTRIEVER 13™ in pazienti con occlusioni vascolari distali di calibro medio (DMVO) nell'ictus ischemico acuto. “Gli ictus di tipo DMVO rappresentano fino al 40% dei casi di ictus ischemico e possono causare una disabil...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--ExaGrid®, jediný skutečně vrstvený systém zálohovacího úložiště na trhu vybavený funkcí AI-Powered Retention Time-Lock (RTL), která zahrnuje i neveřejnou vrstvu (tiered air gap), funkce Auto Detect & Guard, odložené mazání a neměnnost dat pro obnovu po útoku ransomwaru, dnes oznámila, že společnost získala tři ocenění v rámci 1. ročníku udílení ocenění MSP Channel Awards, které se uskutečnilo v Londýně dne 3. prosince 2025. Ocenění zahrnují: Inovace roku...

SOUTHLAKE, Texas et YOQNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, l’un des principaux développeurs de dispositifs endovasculaires actifs, annonce avoir terminé le recrutement des patients pour l’essai DISTALS, une étude randomisée multicentrique évaluant le dispositif TIGERTRIEVER 13™ chez des patients présentant des occlusions distales des vaisseaux moyens (DMVO) lors d’un accident vasculaire cérébral ischémique aigu. « Les accidents vasculaires cérébraux de type DMVO représentent jusqu’à...

MARLBOROUGH, Massachusetts--(BUSINESS WIRE)--ExaGrid®, die branchenweit einzige mehrstufige Backup-Speicherlösung mit KI-gestütztem Retention Time-Lock (RTL), die eine nicht netzwerkgebundene Ebene (Tiered Air Gap) umfasst, Auto Detect & Guard, verzögerte Löschungen und Unveränderlichkeit für die Wiederherstellung nach Ransomware-Angriffen, gab heute bekannt, dass das Unternehmen bei der ersten jährlichen MSP Channel Awards-Zeremonie, die am 3. Dezember 2025 in London stattfand, mit drei Au...

MARLBOROUGH, Massachusetts--(BUSINESS WIRE)--ExaGrid®, la solución exclusiva de la industria con almacenamiento de copias de seguridad por niveles con bloqueo de tiempo de retención (RTL) impulsado por IA que incluye un nivel sin contacto con la red (nivel de separación lógico), la función Auto Detect & Guard para la detección automática y proteccón, eliminaciones con retraso e inmutabilidad para la recuperación ransomware, anunció hoy que la empresa fue galardonada con con tres premios dur...

SOUTHLAKE (Texas) y YOKNEAM (Israel)--(BUSINESS WIRE)--Rapid Medical™, desarrollador líder de dispositivos endovasculares activos, anuncia el cierre de la inscripción de pacientes en la prueba DISTALS, un estudio multicéntrico aleatorizado que evalúa al dispositivo TIGERTRIEVER 13™ en pacientes con oclusiones de vasos medianos distales en accidentes cerebrovasculares isquémicos agudos. “Los accidentes cerebrovasculares por oclusiones de vasos medianos distales representan hasta un 40 por ciento...

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. (“FTA”) announced today approval of the liquidation of First Trust/Confluence Small Cap Value Fund, a series of First Trust Series Fund (the “Fund”). Based upon the recommendation of FTA, the investment advisor of the Fund, the Board of Trustees of First Trust Series Fund determined that it was in the best interests of the Fund to liquidate the Fund. Accordingly, the Board of Trustees approved the liquidation of the Fund pursuant to a pl...

NEW YORK--(BUSINESS WIRE)--On December 9, 2025, the Board of Trustees of BNY Mellon High Yield Strategies Fund (NYSE: DHF) declared from net investment income a monthly cash dividend of $0.0175 per share of beneficial interest, payable on January 9, 2026, to shareholders of record at the close of business on December 23, 2025. The ex-dividend date is December 23, 2025. The previous dividend declared in November was $0.0175 per share of beneficial interest. Important Information BNY Mellon Inves...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective December 5th, 2025, to a non-executive employee of non-qualified stock opt...